Policosonal for dyslipidemia in HIV
The purpose of this study is to evaluate the safety and efficacy of a 12-week course of sugar cane-derived policosanol in a sample of 70 persons with HIV-related dyslipidemia. Safety and efficacy outcomes will be measured at the screening visit and at 0, two, six and 12 weeks. Policosanol is a dietary supplement extracted from purified sugar cane wax. Policosanol has demonstrated tolerability and lipid-lowering properties in non-HIV-infected populations.
You may be eligible to participate in this study if you:
Have a CD4 count greater than 250 cells/mm3
Are between 18 and 60 years of age
Are currently taking HIV medications
This is a partial list of eligibility requirements. To inquire about your specific eligibility, please call the phone number provided.